Skip to content

Immunovant, Inc. IMVT Professional Service Fees Payable

Professional Service Fees Payable at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: Immunovant, Inc.’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s professional service fees payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s professional service fees payable?
Immunovant, Inc. (IMVT) reported professional service fees payable of $1.27M in Q4 2025.
How has Immunovant, Inc.'s professional service fees payable changed year-over-year?
Immunovant, Inc.'s professional service fees payable increased by 978.0% year-over-year, from $118K to $1.27M.
What is the long-term trend for Immunovant, Inc.'s professional service fees payable?
Over 4 years (2021 to 2025), Immunovant, Inc.'s professional service fees payable has grown at a -9.9% compound annual growth rate (CAGR), from $1.2M to $789K.